FDA announces voluntary recall of injectables produced by Coastal Meds

FDA
After Coastal Meds didn’t make the recall public at the request of the FDA, the agency issued an alert to health care professionals. (FDA)

The FDA made public a voluntary recall of sterile injectable drugs produced by compounder Coastal Meds of Biloxi, Mississippi, after visible particles were found in some vials.

The company issued a voluntary recall in early April, however, after Coastal Meds didn’t make the recall public at the request of the FDA, the agency issued an alert to health care professionals not to use and to dispose of the products manufactured by Coastal.

During a recent inspection of the company’s facility, investigators found visible particulates and poor sterile production practices, raising concerns about particulates in Coastal’s drug products intended for injection.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

To date, there have not been any reports of adverse events associated with drug products produced by Coastal. The company is registered as an outsourcing facility.

Read more on

Suggested Articles

Gilead Sciences will donate 1.5 million doses of COVID-19 hopeful remdesivir as its manufacturing of the drug hits light speed.

Sanofi, a hydroxychloroquine maker, is producing as much as it can amid the pandemic, but some workers are having to exit the line manufacturing line.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.